The Americas Cancer Immunotherapy Market forecast projects continued exponential growth, predominantly fueled by the expansion of existing blockbuster drugs into new cancer indications and the commercial launch of novel, platform-based therapies. The forecast is heavily weighted toward the checkpoint inhibitor segment, which is expected to maintain its revenue dominance as combination therapies (e.g., checkpoint inhibitors plus chemotherapy or targeted therapies) become the standard of care for an increasing number of tumor types, including lung, melanoma, and renal cell carcinoma. The steepest growth rate, however, is projected within the cell and gene therapy segment, specifically for CAR T-cell and T-cell Receptor (TCR) therapies, as manufacturing processes are gradually streamlined, and new allogeneic (off-the-shelf) products enter late-stage clinical trials, promising wider patient accessibility.

A crucial factor integrated into the market forecast is the impact of biosimilars. While patent protection for the first wave of monoclonal antibodies begins to expire, the introduction of biosimilar versions is expected to exert downward pressure on unit prices in the long term. However, this may be offset by an increase in patient volume due to improved affordability and broader payer coverage. The forecast for Latin America anticipates significant volume growth, albeit at lower price points compared to the U.S. and Canada, driven by increasing government investment in oncology care and a rising number of clinical trials that provide early access to innovative treatments. Successful companies in this market will be those that effectively manage the complexities of pricing and reimbursement while simultaneously possessing a deep and diversified pipeline that secures future revenue streams through novel therapeutic modalities.